Skip to main content
SpringerLink
Log in

Vigilance, rather than alarm, is needed to manage adverse events associated with bisphosphonate use for osteoporosis

  • Drug Reactions and Interactions
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. Lewiecki EM. Safety of long-term bisphosphonate therapy for the management of osteoporosis. Drugs 2011; 71(6): 791–814

    Article  PubMed  CAS  Google Scholar 

  2. Gold DT. Understanding patient compliance and persistence with osteoporosis therapy. Drugs Aging 2011; 24(4): 249–55

    Article  Google Scholar 

  3. Watts NB, Bilezikian JP, Camacho PM, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract 2010 Nov–Dec; 16Suppl. 3: 1–37

    Article  PubMed  Google Scholar 

  4. Fraunfelder FW, Fraunfelder FT. Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects. Ophthalmology 2004 Jul; 111(7): 1275–9

    Article  PubMed  CAS  Google Scholar 

  5. deGroen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996 Oct 3; 335(14): 1016–21

    Article  PubMed  Google Scholar 

  6. Ettinger B, Pressman A, Schein J, et al. Alendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation. J Managed Care Pharm 1998; 4: 488–92

    Google Scholar 

  7. Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 2003 May; 14(3): 259–62

    PubMed  CAS  Google Scholar 

  8. Musette P, Brandi ML, Cacoub P, et al. Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity. Osteoporos Int 2010 May; 21(5): 723–32

    Article  PubMed  CAS  Google Scholar 

  9. Lewiecki EM, Miller PD. Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. Expert Opin Drug Saf 2007 Nov; 6(6): 663–72

    Article  PubMed  CAS  Google Scholar 

  10. Arase Y, Suzuki F, Suzuki Y, et al. Prolonged-efficacy of bisphosphonate in postmenopausal women with osteoporosis and chronic liver disease. J Med Virol 2008 Jul; 80(7): 1302–7

    Article  PubMed  CAS  Google Scholar 

  11. Crawford BA, Kam C, Pavlovic J, et al. Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2006 Feb 21; 144(4): 239–48

    PubMed  CAS  Google Scholar 

  12. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006 May 16; 144(10): 753–61

    PubMed  CAS  Google Scholar 

  13. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007 Oct; 22(10): 1479–91

    Article  PubMed  Google Scholar 

  14. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007 May 3; 356(18): 1809–22

    Article  PubMed  CAS  Google Scholar 

  15. Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009 Jan 1; 360(1): 89–90

    Article  PubMed  CAS  Google Scholar 

  16. Cardwell CR, Abnet CC, Cantwell MM, et al. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 2010 Aug 11; 304(6): 657–63

    Article  PubMed  CAS  Google Scholar 

  17. Green J, Czanner G, Reeves G, et al. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 2010 Sep 1; 341: c4444

    Article  PubMed  Google Scholar 

  18. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007 Nov 1; 357(18): 1799–809

    Article  PubMed  CAS  Google Scholar 

  19. Heckbert SR, Li G, Cummings SR, et al. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 2008 Apr 28; 168(8): 826–31

    Article  PubMed  CAS  Google Scholar 

  20. FDA safety communication: ongoing safety review of oral bisphosphonates and atypical subtrochanteric femur fractures. Silver Spring (MD): US Food and Drug Administration, 2010 Oct 13

  21. Black DM, Kelly MP, Genant HK, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010 May 13; 362(19): 1761–71

    Article  PubMed  CAS  Google Scholar 

  22. Schilcher J, Michaëlsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011 May 5; 364(18): 1728–37

    Article  PubMed  CAS  Google Scholar 

  23. Caplan L, Pittman CB, Zeringue AL, et al. An observational study of musculoskeletal pain among patients receiving bisphosphonate therapy. Mayo Clin Proc 2010 Apr; 85(4): 341–8

    Article  PubMed  CAS  Google Scholar 

  24. Ringe JD, Body JJ. A review of bone pain relief with ibandronate and other bisphosphonates in disorders of increased bone turnover. Clin Exp Rheumatol 2007 Sep–Oct; 25(5): 766–74

    PubMed  CAS  Google Scholar 

  25. Kanis JA, Reginster JY, Kaufman JM, et al. A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos Int. Epub 2011 Sep 28

  26. Grima DT, Papaioannou A, Airia P, et al. Adverse events, bone mineral density and discontinuation associated with generic alendronate among postmenopausal women previously tolerant of brand alendronate: a retrospective cohort study. BMC Musculoskelet Disord 2010 Apr 14; 11:68

    Article  PubMed  Google Scholar 

  27. Sheehy O, Kindundu CM, Barbeau M, et al. Differences in persistence among different weekly oral bisphosphonate medications. Osteoporos Int 2009 Aug; 20(8): 1369–76

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vigilance, rather than alarm, is needed to manage adverse events associated with bisphosphonate use for osteoporosis. Drugs Ther Perspect 28, 20–23 (2012). https://doi.org/10.2165/11606290-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11606290-000000000-00000

Search

Navigation